Elizabeth Alcamo

Liz is an Entrepreneur-in-Residence at Versant and Chief Business Officer at the firm's portfolio company, Seawolf Therapeutics.

Prior to becoming an EIR, Liz was SVP of Corporate Development at Versant’s Inception Therapeutics discovery engine, where she drove new company sourcing and played an integral role in operationalizing two Series A companies. Previously, Liz held various leadership roles driving corporate, science and IP strategy and business development at several emerging gene therapy companies including Avalanche Biotechnologies (now Adverum), 4D Molecular Therapeutics and CODA Biotherapeutics.